Investors & Media

To effectively manage increased patient volumes and financial demands, healthcare organizations are adopting solutions for electronic patient records and systems that allow them to share patient information in real-time. This segment of e-health is growing, and the growth is expected to accelerate in the coming years. Ortivus is well-positioned to capitalize on this development.

Ortivus shares have been listed on the NASDAQ Stockholm Small Cap-lista since January 2, 1997.

	Stock Symbol	ISIN	Shares Outstanding	Votes/share	Total Number of Votes
Class A	ORTI A	SE0000188930	1,662,682	10	16,626,820
Class B	ORTI B	SE0000123085	42,644,786	1	42,644,786

The share capital is SEK 15,507,614. Share capital is divided between class A and class B shares. The number of shares outstanding is 44,307,468 of which class A amount to 1,662,682 and class B to 42,644,786. Every class A share carries 10 votes and every class B share carries one vote.  

Ortivus A

Ortivus B

Hover the mouse over the graphs to see the share price at the corresponding date.  

Top 10 Shareholders as per 30th of September 2020

		Number of shares	Share of Capital
PONDERUS INVEST AB	Series A Series B Total	13 177 10 360 762 10 373 939	23.3%
NORDNET PENSIONSFÖRSÄKRING A	Series A Series B Total	33 593 3 955 703 3 989 296	9.0%
FÖRSÄKRINGS AB AVANZA	Series A Series B Total	54 299 3 711 161 3 765 460	8.5%
PETTERSSON, RUNE	Series B	2 802 620	6.3%
FRAIM, ING-MARIE	Series B	1 974 087	4.5%
RASPART FÖRVALTNING AB	Series B	1 850 418	4.2%
ADOLFSSON, PER-OLA	Series B	1 597 963	3.6%
SELIGSON & CO PHOENIX FUND	Series B	1 554 795	3.5%
ERIKSSON, NILS-ARNE	Series B	1 550 625	3.5%
GAGAB AB	Series B	824 659	1.9%
Sum of top 10 shareholders			68.4%

 

       

Subscribe to Financial Information 

• Annual General Meeting 2020: 5/5 2021, 16:30-18:00
• Interim report Q2 2020: 21/08 2020, 08.30 am
• Interim report Q3 2020: 10/11 2020, 08:30 am
• Yearend report Q4 2020: 16/2 2021, 08.30 am
• Interim report Q1 2021: 27/4 2021 kl 08.30

• Ortivus protokoll årsstämma 2019
• Ortivus protokoll årsstämma 2019 bilagor 2-4
• Ersättning till ledande befattningshavare revisorns yttrande
• Fullmaktsblankett
• Kallelse till årsstämma i Ortivus AB
• Ortivus styrelsen redovisning av resultatet av ersättningskommitten
• Ortivus valberedningens arbete 2019
• Ortivus valberedningens motiverade yttrande 2019
• Styrelsens förslag till riktlinjer för ersättning till ledande befattningshavare

PREVIOUS AG MEETINGS

The board of Ortivus AB (publ) has decided to carry out a 100% secured rights issue of approximately SEK 9 million. The Board’s decision is conditional on the approval of the forthcoming Extraordinary General Meeting, which will be held on February 18, 2019. The proposed pre-emptive share issue intends to improve the Company’s financial position while allowing for continued development of the Company’s operations. (Documents below are in Swedish only)

1. Fullmaktsblankett
2. Styrelseprotokoll
3. Redogörelse av styrelsen enligt ABL 13-6
4. Kallelse
5. Revisorsyttrande
6. Protokoll extra bolagsstämma i Ortivus

The Board of Directors of Ortivus AB (publ) has, on the basis of authorization from the Annual General Meeting 2019, decided on a new issue comprising 7,500,000 new B shares directed at a small number of specially selected investors. The total share issue raises SEK 15 million before costs for issuing of new shares. The new shares are issued at a subscription price corresponding to SEK 2 per share. The subscription price has been determined on a market basis and corresponds to the volume-weighted price of the company’s B shares during the last 20 trading days with a mark-up of 5%. The investors who signed up for the directed new share issue have undertaken not to sell the newly issued shares within 6 months from the Board’s decision, so-called Lock-up. The rights issue is carried out with the aim of securing further financing of the company’s working capital and the continued development of the company’s operations. Download the prospectus (in Swedish) “Ortivus-AB-(publ)_Prospekt-avseende-upptagande-till-handel-av-nyemitterade-aktier_2019-07-10” here.